Pcn345 a Review of Differences in Decision-Making Across Nice Health Technology Assessments of Nivolumab

Abstract

Excellence (NICE) states that technology appraisals (TAs) should continue to use EQ-5D-3L. The aim of this review was to establish if and how EQ-5D-5L is being used in NICE TAs. Methods: A review of published NICE TAs within tumour-based oncology diseases was conducted. TAs were included if: guidance had been published after January 2018; a company submission was available; and an evidence review group (ERG) critique was available. Results: Thirty-two TAs were identified; 8 (25%) and 18 (56%) obtained utilities from the EQ-5D-5L and EQ-5D-3L questionnaires, respectively; 4 (13%) used condition specific quality-of-life measures, and in 2 (6%) it was unclear whether 3L or 5L was used. The number of TAs which utilised EQ-5D-5L has almost doubled from 2018 to 2019. All 8 EQ-5D-5L TAs mapped 5L utilities to 3L utilities using the Van Hout 'cross-walk' algorithm; 1 at the request of the ERG (TA528, BMJ-TAG) and 7 prior to the initial submission. Of the 8 TAs, 4 presented sensitivity analyses, all of which demonstrated an improvement in the cost-effectiveness when EQ-5D-5L was used. Conclusions: This review suggests that manufacturers are continuing to use EQ-5D-3L over EQ-5D-5L. However, some TAs found that when EQ-5D-5L utilities are used, cost-effectiveness may be improved. Although the use of the EQ-5D-5L questionnaire in appraisals appears to be increasing, its impact on NICE TAs remains limited.